2 / 6
Page 9
December 09-10, 2019 | Barcelona, Spain
Volume 02
Journal of Immune Disorders & Therapy
J Immune Disord Ther, Volume 02
World Immunology 2019 & Cancer Summit 2019
December 09-10, 2019
9
th
WORLD CONGRESS ON
IMMUNOLOGY AND CANCER
Oxsealife: Embarking on a newmethodology to treat haemorrhagic shock that focuses
on cell recovery
H
aemorrhagic shock is the result of inadequate blood flow to meet the metabolic demands of organs resulting in a
flow dependent impairment of oxygen consumption by cells. Severe hemorrhage and ischaemia triggers a cascade of
intracellular events that induce mitochondrial dysfunction and multiorgan failure. Therefore, patient survival after severe
haemorrhagic shock depends on restoration of microvascular perfusion, tissue oxygen delivery, endothelial function and cell
integrity. We investigated a novel crystalloid fluid designed for tissue oxygen delivery, Oxsealife®, with components to generate
microvascular nitric oxide and scavenge reactive oxygen species generated during ischaemia-reperfusion injury. The amount
of dissolved oxygen in blood progressively increased during step-wise
in-vitro
haemodilution with this fluid, demonstrating
that the oxygen solubility coefficient of blood is dynamic, not static. We performed a pilot study to compare resuscitation
with this novel crystalloid vs whole blood transfusion in a swine haemorrhagic shock model with animals bled to an arterial
lactate oxygen debt target. Despite contributing no haemoglobin, viscosity nor
oncotic potential, resuscitation with Oxsealife® after severe haemorrhagic shock
restored central haemodynamic parameters comparable to stored allogeneic blood
transfusion. Tissue perfusion, oxygenation and metabolic outcomes were equivalent
between treatment groups. Increased consumption of bicarbonate in animals given
Oxsealife® suggested greater capillary recruitment and enhanced clearance of lactate
accumulated in tissues. Serum markers of organ function, animal activity during
recovery, and histological analysis of tissue morphology and endothelial glycocalyx
integrity confirmed functional recovery from haemorrhagic shock. We conclude that
recovery of tissue oxygen delivery and organ function after haemorrhagic shock is
not dependent on treatments that increase haemoglobin levels. Oxsealife® shows
promise for treatment of severe haemorrhagic shock, and may reduce requirement
for allogeneic blood products.
Biography
Lara Oller discovered the field of bloodless medicine and surgery when she was 12 years old and at that early age, she decided to commit
her professional life to searching for the blood substitute. She studied medicine and was trained as anesthesiologist for this very reason.
During her second year of training specialization she started and developed the project named “Oxsealife” which is an enhanced approach
to haemorrhagic shock treatment and cell recovery after injury. The project also involves the renewal of the physiological fundamentals of
oxygen transport. Professor Aryeh Shander, her dear mentor and associate, has been a highly valuable asset from the very beginning and
now a recent collaboration with Wayne B Dyer has been achieved to expand animal studies before we get to human trials. She owns the
Oxsealife patent and Dr Shander appears as a co-inventor. She is completely committed to this project and she is pleased to see it grow.
oller.paris@gmail.comLara Oller
Hospital La Luz, Spain